Literature DB >> 9012693

Clinical characteristics predict response to antithymocyte globulin in paroxysmal nocturnal haemoglobinuria.

R L Paquette1, R Yoshimura, C Veiseh, L Kunkel, J Gajewski, P J Rosen.   

Abstract

Seven patients with paroxysmal nocturnal haemoglobinuria (PNH) were treated with antithymocyte globulin (ATG). Each patient received ATG (20 mg/kg/d) for 8 d and prednisone to prevent or control serum sickness. Three patients experienced a sustained improvement in at least one peripheral blood cytopenia, including one patient who had a complete trilineage response. Several pretreatment clinical features appeared to be associated with response to ATG. All responding patients had hypoproliferative features including depressed platelet counts (< 30 x 10(9)/l), and a minor degree of chronic haemolysis as indicated by relatively low reticulocyte counts (< 100 x 10(9)/l), lactate dehydrogenase (< 1000 U/l) and total bilirubin (< 17 mumol/l) levels. Responding patients continued to have chronic low-grade haemolysis after their response to immunosuppression that was similar to that observed prior to treatment. The non-responding patients had a classic haemolytic form of PNH characterized by elevated reticulocyte counts (> 100 x 10(9)/l), lactate dehydrogenase (> 2000 U/l) and total bilirubin (> 17 mumol/l) levels. The impaired haemopoiesis that occurs in hypoproliferative PNH may respond to ATG treatment, but the haemolytic component of the disease, and hence the PNH clone, is not altered by immunosuppressive therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9012693     DOI: 10.1046/j.1365-2141.1997.d01-1984.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

Review 1.  New insights into molecular pathogenesis of bone marrow failure in paroxysmal nocturnal hemoglobinuria.

Authors:  Tatsuya Kawaguchi; Hideki Nakakuma
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

2.  Neutral evolution in paroxysmal nocturnal hemoglobinuria.

Authors:  David Dingli; Lucio Luzzatto; Jorge M Pacheco
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-14       Impact factor: 11.205

3.  The status of antithymocyte globulin therapy for adult patients in Japan: retrospective analysis of a nationwide survey.

Authors:  Mamiko Hattori; Teruhiko Terasawa; Keitaro Tsushita; Makoto Utsumi; Fumio Kawano; Hidehiko Saito; Masanori Shimoyama; Haruhiko Ohashi
Journal:  Int J Hematol       Date:  2007-12-08       Impact factor: 2.490

4.  Paroxysmal nocturnal hemoglobinuria in childhood and adolescence--a retrospective analysis of 18 cases.

Authors:  Rahul Naithani; Manoranjan Mahapatra; Pankhi Dutta; Rajat Kumar; Hara Prasad Pati; Ved Prakash Choudhry
Journal:  Indian J Pediatr       Date:  2008-08-31       Impact factor: 1.967

Review 5.  The Role of T Lymphocytes in the Pathogenesis of Paroxysmal Nocturnal Hemoglobinuria.

Authors:  Chenyuan Li; Xifeng Dong; Huaquan Wang; Zonghong Shao
Journal:  Front Immunol       Date:  2021-12-24       Impact factor: 7.561

6.  Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria.

Authors:  Raymond S M Wong; Humphrey W H Pullon; Ismail Amine; Andrija Bogdanovic; Pascal Deschatelets; Cedric G Francois; Kalina Ignatova; Surapol Issaragrisil; Pimjai Niparuck; Tontanai Numbenjapon; Eloy Roman; Jameela Sathar; Raymond Xu; Mohammed Al-Adhami; Lisa Tan; Eric Tse; Federico V Grossi
Journal:  Ann Hematol       Date:  2022-07-22       Impact factor: 4.030

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.